The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

NANot yet recruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions
Cardiovascular Diseases
Interventions
BEHAVIORAL

Guideline education and implementation intervention

"The intervention is implemented at the investigator level and the patient level, consisted of 3 parts:~1. Disease education~ * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.~ * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.~2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.~3. Follow-up management:the subjects will be followed up every 4 weeks."

Trial Locations (3)

100029

Research Site, Beijing

100191

Research Site, Beijing

201114

Research Site, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY